Shopping Cart 0
Cart Subtotal
AED 0

KOL Perspectives: Update on Novel Candidates in Development for Lupus

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 9175

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
AED 18350

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 27525

Details

KOL Perspectives: Update on Novel Candidates in Development for Lupus

Summary

This KOL Insight briefing provides an update on novel candidates in development for Lupus.

The briefing includes analysis of KOL opinion on the following topic areas-

- Atacicept's efficacy data in SLE

- Atacicept's flare data in SLE

- Patients most suitable for atacicept treatment

- Targeting the IgE pathway in lupus

- Omalizumab'sefficacy data in SLE

- Omalizumab'ssafety data in SLE

- Lupuzor's Phase III efficacy data

- Impact of lupuzor's Phase III data on existing opinion of lupuzor

- Lupuzor's Phase III safety data in SLE

- Anticipated future use of lupuzor in clinical practice

Key Highlights

- Most KOLs had a positive opinion of atacicept's efficacy in SLE despite failure to achieve its primary endpoint of SRI-4 in the ITT population

- KOL opinions were divided in terms of targeting the IgE pathway in lupus, with some unaware of any scientific rationale behind it

- Most KOLs were disappointed by lupuzor's Phase III efficacy data but were not surprised by the high placebo response rate observed in the trial.

Scope

- The insight briefing is based on Sociable Pharma's analysis of primary research with our lupus key opinion leaders (KOLs)

- In total, we conducted interviews with 10 KOLs: Five Europe-based & fuve US-based

- Interviews performed in Q2 2018

- KOL data is analyzed to produce: Charts summarizing KOL opinions

- Chart call-outs of key information & details

- KOL quotes

- Summary of KOL reporting trends

- Insight from Sociable Pharma's analysts.

Reasons to buy

- Combines Qualitative & semi-quantitative insight from key opinion leaders on "Novel Candidates in Development for Lupus"

- Includes insight & recommendations from our disease-specific healthcare analysts

- Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of Lupus

- Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.

READ MORE

Table Of Content

Scope

Table of Contents

Executive Summary

Background

Research Panel Composition

Results & Implications

Appendix

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Lupus, Atacicept, IgE, Omalizumab, Lupuzor


Companies

EMD Serono

Novartis

Roche

Genentech

ImmuPharma

Company Profile

Company Profile Title

KOL Perspectives: Update on Novel Candidates in Development for Lupus

Summary

This KOL Insight briefing provides an update on novel candidates in development for Lupus.

The briefing includes analysis of KOL opinion on the following topic areas-

- Atacicept's efficacy data in SLE

- Atacicept's flare data in SLE

- Patients most suitable for atacicept treatment

- Targeting the IgE pathway in lupus

- Omalizumab'sefficacy data in SLE

- Omalizumab'ssafety data in SLE

- Lupuzor's Phase III efficacy data

- Impact of lupuzor's Phase III data on existing opinion of lupuzor

- Lupuzor's Phase III safety data in SLE

- Anticipated future use of lupuzor in clinical practice

Key Highlights

- Most KOLs had a positive opinion of atacicept's efficacy in SLE despite failure to achieve its primary endpoint of SRI-4 in the ITT population

- KOL opinions were divided in terms of targeting the IgE pathway in lupus, with some unaware of any scientific rationale behind it

- Most KOLs were disappointed by lupuzor's Phase III efficacy data but were not surprised by the high placebo response rate observed in the trial.

Scope

- The insight briefing is based on Sociable Pharma's analysis of primary research with our lupus key opinion leaders (KOLs)

- In total, we conducted interviews with 10 KOLs: Five Europe-based & fuve US-based

- Interviews performed in Q2 2018

- KOL data is analyzed to produce: Charts summarizing KOL opinions

- Chart call-outs of key information & details

- KOL quotes

- Summary of KOL reporting trends

- Insight from Sociable Pharma's analysts.

Reasons to buy

- Combines Qualitative & semi-quantitative insight from key opinion leaders on "Novel Candidates in Development for Lupus"

- Includes insight & recommendations from our disease-specific healthcare analysts

- Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of Lupus

- Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.

READ MORE

Scope

Table of Contents

Executive Summary

Background

Research Panel Composition

Results & Implications

Appendix

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Lupus, Atacicept, IgE, Omalizumab, Lupuzor


Companies

EMD Serono

Novartis

Roche

Genentech

ImmuPharma